AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKI
MD Anderson Study Status
BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.